Phio Pharmaceuticals Corp Dossier
Qualitative Analysis
Business overview
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company's proprietary core platform is its INTASYL® siRNA gene silencing technology, which is designed to down-regulate specific gene expressions to make immune cells more effective at targeting and destroying tumor cells. Phio's lead clinical candidate is PH-762, a potent silencer of the PD-1 gene being developed as an intratumoral immunotherapy for skin cancers, including cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead INTASYL self-delivering RNAi compound, PH-762, which silences the PD-1 gene, for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Expected impact: Establishment of PH-762 as a first-in-class, non-surgical intratumoral immunotherapy for skin cancers.
Securing capital through equity financings, warrant exercises, and at-the-market (ATM) offerings to fund clinical development and extend the cash runway.
Expected impact: Sustained operational funding to achieve key clinical and regulatory milestones without immediate liquidity shortfalls.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides analytical, process development, and cGMP manufacture of the lead development compound PH-762 to support future pivotal clinical development.
Terms: Not disclosed
Conducts the non-clinical toxicology study required by the FDA prior to commencing a pivotal human clinical trial of PH-762 for registration purposes.
Terms: Not disclosed